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Summary
Objective: Non-animal stabilized hyaluronic acid (NASHA) is a novel hyaluronan (HA) preparation with a 4-week intra-articular half-life. This
study compared the efﬁcacy of a single injection of NASHA with placebo in patients with osteoarthritis (OA) of the knee.
Design: This was a 26-week randomized, double-blind, multicenter study of a single intra-articular knee injection with either NASHA or
placebo (saline). Assessments included the Western Ontario McMasters Universities osteoarthritis index (WOMAC, Likert Scale) and patients’
overall global disease status. A positive response was deﬁned as a reduction in WOMAC pain score for the study knee of 40% from baseline
with a minimum improvement of R5 points.
Results: A total of 346 (NASHA 172; placebo 174) patients were treated. WOMAC scores and quality of life were improved in both the NASHA
and placebo groups. For the overall population, there were no statistically signiﬁcant between-group differences in response rates for any
efﬁcacy parameters. In patients with OA conﬁned to the knee (N ¼ 216), a greater response to NASHA than placebo was observed at week 6
(P ¼ 0:025). There were few treatment-related events.
Conclusions: NASHA was not superior to placebo for the primary efﬁcacy analysis. However, these data may be confounded by the inclusion
of patients with OA at other sites, as signiﬁcant beneﬁts over placebo were found among patients with OA conﬁned to the knee. Future trials of
OA that examine a local therapy might need to consider restricting the study population to those patients having OA of only the signal joint.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis1,2,
and is often debilitating3,4. OA has become the most costly
form of arthritis5, collectively accounting for up to 1e2.5% of
the gross national product of Western nations2. The preva-
lence of OA increases with age, with more than 60% of
those over 60 years old likely to have some cartilage
abnormality in a major joint6.
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directed at symptoms, primarily pain. The focus has been
on non-pharmacologic measures with analgesics and anti-
inﬂammatory drugs7,8. Intra-articular corticosteroids and
hyaluronic acid (hyaluronan; HA) therapy have supple-
mented this approach.
HA is a widely distributed, linear glycosaminoglycan
constituent of cartilage, synovial ﬂuid, skin and aqueous
humor, identical in all forms of biological life. HA lubricates
synovial joints, assists with shock-absorption and structure-
stabilization and has direct effects on synovial cell function.
Furthermore, in vitro data indicate that HA may slow chon-
drocyte apoptosis in OA by binding CD44 and ICAM-1
receptors, thereby regulating the processes of cartilage
matrix degradation9. Synovial ﬂuid from arthritic joints
contains lower concentrations of HA than that from normal
joints10. As the elasticity and viscosity of synovial ﬂuid are
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articular injection of HA is a rational approach to the
treatment of OA. Use of HA in human arthritic knees was
ﬁrst investigated in the 1970s10 with efﬁcacy and safety
subsequently demonstrated in knees and other joints in
several studies11e15. Multiple injections of most HA prepa-
rations are required to achieve efﬁcacy; perhaps due to
a short residence time in the joint12. Most currently used HA
preparations are derived from rooster-comb tissue and,
although puriﬁcation processes have improved in recent
years, there remains at least a theoretical risk of impurities
such as proteins, viruses or other materials of animal origin.
Some adverse effects of injected HA may be attributable
to impurities of biological origin. Non-animal stabilized
hyaluronic acid (NASHA) is synthesized by Streptococci
and is readily puriﬁed furtherdthus the risk of contamina-
tion with materials of animal origin is minimal. The
stabilization process (carefully controlled cross-linking of
HA) creates a somewhat viscous gel with increased density
of HA, without changing the polyanionic character of the
polysaccharide chain thus retaining its biocompatibility16.
The resulting prolonged residence time in the joint may
allow reduced number of injections to achieve long-term
efﬁcacy in the treatment of OA.
This study was performed to investigate the safety and
efﬁcacy of single-injection NASHA compared with placebo
in patients with OA of the knee.
Methods
This randomized, double-blind, multicenter study was
conducted in accordance with the Declaration of Helsinki
and the World Medical Assembly and its amendments. The
study protocol and subsequent protocol amendments were
reviewed and approved by local Ethics Committees at the
investigative sites. Written informed consent was obtained
and the study performed in accordance with the Interna-
tional Conference on Harmonization Guidelines for Good
Clinical Practice.
STUDY POPULATION
Patients were recruited from 18 centers across the USA
(N ¼ 7), Canada (N ¼ 6) and Sweden (N ¼ 5). Inclusion
criteria were: OA of the knee as deﬁned by the American
College of Rheumatology criteria17 that was refractory to
non-pharmacologic therapies; a Western Ontario McMas-
ters Universities osteoarthritis index (WOMAC; Likert scale)
pain subscale score (range 0e20) of at least 7 in one knee
and no greater than 15 in either knee; and signiﬁcant knee
pain in the signal knee for the majority of the preceding 3
months (patients had to be normally active and able to walk
50 m, unaided). Exclusion criteria included: isolated patel-
lofemoral OA; use of systemic steroids, glucosamine or
chondroitin within the past 3 months; intra-articular injection
into the knee of corticosteroids in the past 3 months or intra-
articular HA within the last 9 months; treatment with oral or
topical NSAIDs during the previous week; use of topical
non-NSAIDs within the previous 3 days; arthroscopy or
other surgical procedure within the last 12 months and
anticoagulant treatment (except acetylsalicylic acid,
%325 mg/day). Patients were also excluded if they pre-
sented with a systemic active inﬂammatory condition or
infection, septic knee arthritis within the previous 3 months,
signiﬁcant venous or lymphatic stasis of the legs, active skin
disease or infection at the injection site, or any othermedical condition rendering the patient unsuitable for
inclusion according to the investigator. Pregnant or breast-
feeding women and those of childbearing potential not
practicing adequate contraception were ineligible.
STUDY DESIGN
Patients fulﬁlling the inclusion and exclusion criteria were
randomized (1:1) to either NASHA (Durolane, Q-Med AB,
Uppsala, Sweden) or saline administered intra-articularly
into the study knee. The randomization list was prepared by
Q-Med. Patients who had passed the eligibility check and
who had completed the baseline efﬁcacy assessments
were allocated patient numbers in consecutive order. The
packaging for each syringe was labeled with the appropriate
patient number (according to the randomization list) prior to
shipment to the study center. The treating investigator
documented the IA injection in the CRF. The performance
of all patient assessments by an evaluating investigator,
blinded to the randomization code, ensured that the study
was blinded. Additionally, patients were not informed of
which treatment they received. For patients with bilateral
OA, the study knee was designated the knee with the higher
WOMAC pain score, or the clinically worse-affected knee
(clinically, radiographically) if there was no difference in
WOMAC score. The study consisted of a screening visit,
a baseline visitdduring which intra-articular injection was
madedand follow-up visits at 2, 6, 13, and 26 weeks.
Patients randomized to NASHA received a single 3 ml
injection. The study product contained HA 60 mg in buffered
sodium chloride, 0.9% (pH 7). The placebo contained the
identical buffered sodium chloride vehicle used in the study
product. Both NASHA and placebo were supplied in
identical 3 ml syringes. The recommended needle size for
injection was 18e22 G.
Acetaminophen (paracetamol; maximum daily dose, 4 g)
was permitted as rescue medication except during the 48-h
period prior to each study visit. Use of rescue medication
was recorded in a patient diary.
Blinding of the evaluating investigator was achieved by
ensuring that the treating clinician who administered the
injection was not involved in conducting the clinical evalua-
tions. As an assessment of masking, both the evaluating
investigator and patient were asked to hypothesize at
baseline (immediately after treatment) and at the 26-week
visit whether NASHA or saline had been injected.
CLINICAL ASSESSMENTS
The WOMAC pain subscale was assessed at the
screening visit. The screening visit included collection of
demographic information (Table I). Information on OA of
other joints was historical and conﬁrmed by physical
examination. Clinical assessments were subsequently
performed at baseline and at follow-up at each regularly
scheduled visit.
A responder (positive response to treatment)dthe
primary endpointdwas deﬁned as a reduction in the
WOMAC pain score of at least 40% with an absolute
improvement of at least 5 points compared with baseline for
the study knee at the ﬁnal visit18. Secondary outcome
measures included the WOMAC stiffness score, WOMAC
physical function score, and patient assessment of global
disease status on a 5-point scale. The 36-item short form
health survey (SF-36) was completed as a quality-of-life
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weeks.
Adverse events were both reported by the patient and
observed by the investigator. The occurrence of all adverse
events (AEs) was recorded, including a description of the
event, duration, causality, grading (serious/non-serious),
intensity, action taken and outcome.
STATISTICAL METHODS
The sample size was based on testing for a difference
between the two treatment groups at the 5% signiﬁcance
level (80% power), assuming response rates of 35% to
Durolane and 20% to placebo. This resulted in a sample
size of 138 patients in each group, 276 in total.
Table I
Baseline characteristics of the study population
Variable NASHA (N ¼ 172) Saline (N ¼ 174)
Age in years
[mean (range)]
62.9 (41e85) 63.3 (35e85)
Women:Men
[n (%)]
79/93 (46:54) 111/63 (64:36)
BMI women
[mean (range)]
31.3 (21.4e61.1) 29.8 (18.4e54.6)
BMI men
[mean (range)]
29.5 (21.7e44.4) 29.0 (22.2e41.4)
Duration of OA in
years [mean (range)]
5.0 (0.0e45.5) 6.5 (0.0e50.5)
Kellgren Lawrence grade [n (%)]
Grade 2 40 (23) 39 (22)
Grade 3 92 (53) 90 (52)
Grade 4 40 (23) 45 (26)
Previous treatment [n (%)]
NSAIDs or analgesics 146 (85) 142 (82)
Glucosamine 50 (29) 51 (29)
Intra-articular
depocorticosteroids
62 (36) 56 (32)
Intra-articular
hyaluronate
37 (22) 34 (20)
Previous knee
surgery [n (%)]y
63 (37) 57 (33)
Joint effusion
[n (%)]y
46 (27) 74 (43)
Tenderness on
palpation [n (%)]y
110 (64) 102 (59)
WOMAC pain
[mean (range)]y
9.90 (6e15) 10.42 (7e15)
WOMAC pain of
non-study knee
[mean (range)]
4.84 (0e14) 4.63 (0e15)
WOMAC stiffness
[mean (range)]
3.91 (0e8) 4.30 (0e7)
WOMAC physical
function [mean (range)]
30.70 (5e61) 32.16 (2e59)
Patient’s assessment,
global status
[mean (range)]
3.23 (1e5) 3.17 (1e5)
SF-36, physical
component summary
[mean (range)]
33.54 (15.1e54.5) 32.91 (14.1e53.2)
SF-36, mental
component summary
[mean (range)]
55.55 (25.8e72.8) 55.92 (27.2e70.9)
NASHAZnon-animal stabilized hyaluronate; BMIZbody mass
index; OAZosteoarthritis; NSAIDsZnon-steroidal antiinﬂammatory
drugs; WOMACZWestern Ontario McMasters University
Osteoarthritis Index; SF-36Zshort form 36.
yOf study (signal) knee.Statistical analyses were based on an intention-to-treat
(ITT) principle. The null hypothesis of no difference in
responder rate between the two treatments at 26 weeks
was analyzed using logistic regression approach with
treatment as the main effect. The impact of relevant
covariates was explored by their inclusion in the main
effect model. The ITT analysis was performed using the last
observed data. For patients who were prematurely
withdrawn from the study the missing data after dropout
were replaced with the last observed value according to the
principle of last observation carried forward (LOCF). There
were no baseline differences between those completing the
study and those not completing the study in demographic or
clinical characteristics.
The Wilcoxon rank sum test was used to compare the
treatment groups with respect to change from baseline in
WOMAC pain, WOMAC stiffness and WOMAC physical
function scores. Comparison of the groups with respect to
change in patient assessment of global status from baseline
was made after adjustment for the WOMAC pain score in
the untreated knee. This was made by performing ordinal
logistic regression, using the proportional odds model.
Analysis of the SF-36 involved calculating the Physical
Component Summary (PCS) and Mental Component
Summary (MCS) for each patient. Wilcoxon rank sum test
was used to test the change from baseline between the
treatment groups. There was no adjustment for multiple
comparisons in the secondary analyses.
Results
PATIENT CHARACTERISTICS
A total of 454 patients were screened, of whom 347
(76%) were randomized to treatment and hence included in
the safety analysis (Fig. 1). The ITT population comprised
346 patients (172 NASHA and 174 saline recipients) and
were included in the efﬁcacy analysis. The remaining
randomized patients did not receive treatment due to pain
on the initial attempted needle insertion; the injection was
aborted. Seventy-four patients did not complete the study
(39 NASHA and 35 saline recipients), and the per protocol
population comprised 232 patients (113 NASHA and 119
saline).
The demographics and baseline characteristics of the
study population are recorded in Table I. Although statistical
comparison was not performed, the two treatment groups
appeared comparable with the following exceptions: there
was a trend towards higher WOMAC pain, stiffness and
physical function scores in the saline group. Also, there
were more women in the saline group than the NASHA
group and the incidence of joint effusion in the signal knee
at screening was greater in the saline group.
EFFICACY EVALUATIONS
Overall response
The response rate with NASHA reached 29.1% by week
2, and remained at or above this level out to 26 weeks, with
a maximum response rate of 36.6% occurring at 6 weeks
post-treatment (Table II). However, by ITT or per protocol
analysis, there was no signiﬁcant difference between the
number of responders between placebo and NASHA
groups at 26 weeks (the primary efﬁcacy variable). The
number of responders changed little between 2 and 26
weeks for both groups, while there were no between-group
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Allocation
Follow-up
Analysis
Allocated to NASHA (N=173)
Received allocated intervention
(N=172): one patient declined
injection
Allocated to saline (N=174)
Received allocated intervention
(N=174)
Premature discontinuation (N=39)
Adverse event (N=13)
Consent withdrawn (N=11)
Lost to follow-up (N=2)
Protocol violation (N=1)
Other reasons* (N=10)
Premature discontinuation (N=35)
Adverse event (N=6)
Consent withdrawn (N=16)
Lost to follow-up (N=5)
Protocol violation (N=2)
Other reasons* (N=6)
Analysed [ITT population]
(N=172)
Completers (N=133)
Knee OA only, ITT (N=107)
Knee OA only, completers
(N=77)
Analysed [ITT population]
(N=174)
Completers (N=139)
Knee OA only, ITT (N=109)
Knee OA only, completers
(N=81)
Randomized (N=347)
Screened (N=454)
Fig. 1. Study population.differences in response rate at any of the time-points
evaluated in this study, for either the ITT or per protocol
population.
Among patients who were classiﬁed as responders at 6
weeks, 59% in the NASHA group remained as responders
at 26 weeks; however, this compared with 56% in the
saline group. Conversely, 87% of patients in the NASHA
Table II
Response rates in all patients and in those with OA confined to the
knee
Weeks
2 6 13 26
ITT
NASHA (N ¼ 172) 29.1 36.6 32.0 29.1
Placebo (N ¼ 174) 36.2 29.9 35.1 32.2
Per protocol
NASHA (N ¼ 113) 32.7 42.5 38.1 36.3
Placebo (N ¼ 119) 41.2 34.5 40.3 37.8
Knee only, ITT
NASHA (N ¼ 107) 33.6 42.1* 35.5 30.8
Placebo (N ¼ 109) 34.9 27.5* 33.0 32.1
Knee only, per protocol
NASHA (N ¼ 77) 33.8 46.8* 39.0 36.4
Placebo (N ¼ 81) 37.0 29.6* 37.0 35.6
*Statistically signiﬁcant difference, NASHA vs placebo.group who were non-responders at 6 weeks remained as
non-responders at the subsequent two follow-up visits;
the corresponding proportion was 72% in the saline
group, perhaps indicating a lower degree of ﬂuctuation
between response and non-response in the active treat-
ment group.
The WOMAC pain, stiffness and physical function scores
in both groups decreased over the study period (Table III).
There was no signiﬁcant between-group difference in
WOMAC pain score in the study knee at any follow-up
time-point; small but signiﬁcant differences in favor of saline
were observed in WOMAC stiffness score (2 weeks and 6
months) and physical function score (2 weeks). The change
from baseline in patient assessment of global status and
SF-36 did not differ signiﬁcantly between treatment groups
at any time-point assessments.
At baseline, the majority of all patients guessed that
NASHA had been administeredd80% in the NASHA group
compared with 71% in the placebo group. The correspond-
ing proportions for investigators were 68% and 66%,
respectively. At 26 weeks, the proportion of patients
guessing NASHA was 55% in the NASHA group, compared
with 44% in the saline group; for investigators, these
proportions were 46% and 38%, respectively.
SUBGROUP ANALYSIS
Within the overall ITT population, 216 patients had OA
conﬁned to the knee (Fig. 1). Among this patient subgroup,
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021.3% recorded use of NSAIDs or analgesics until baseline
compared with 38.5% in patients with OA at other sites.
Mean WOMAC pain scores (study knee) for the two
subgroups were 10.0 and 10.4, respectively. Mean intake
of rescue medication during the ﬁrst 6 weeks of the study
was 7 g in patients with OA conﬁned to the knee, compared
with 24 g in those with OA at other sites.
Patients with OA conﬁned to the knee demonstrated
a greater response following NASHA treatment compared
with the overall study population (Fig. 2; Table II).
Accordingly, those on NASHA had a signiﬁcantly greater
response rate compared with saline at 6 weeks (P!0:025).
Eighty-two patients within this subgroup (38%) had OA
localized only to the study knee with no other joints affected
by OA. The response rate associated with NASHA treat-
ment was more pronounced in these patients (N ¼ 38)
compared with saline recipients (N ¼ 44) at 6 weeks
(47.4% vs 20.1%; P!0:0097).
SAFETY EVALUATION
The safety evaluation included all recruited patients
(N ¼ 347) (Table IV). A total of 513 AEs were reported by
227 patients (65.4%) over the study period. The majority of
AEs (79.3%) were classiﬁed as mild/moderate. The number
of patients reporting treatment-related AEs was 22 (12.8%)
in the NASHA group, and 14 (8.0%) in the saline group. The
most common treatment-related AE was arthralgia, re-
ported by 11 patients (6.4%) and 5 patients (2.9%) in the
NASHA and saline groups, respectively. The majority of
treatment-related AEs (O70%) were reported within 2 days
of injection in both treatment groups.
Treatment withdrawal attributable to AEs occurred in 13
and 6 patients in the two groups, respectively; 5 and 4 of
these events were considered related to treatment. Of the
nine treatment-related AEs leading to withdrawal, seven
were knee pains, one was worsening OA pain in the knee
(NASHA group), and one was knee synovitis (placebo
group). Ten patients (seven in the NASHA and three in the
saline group) reported serious adverse events (SAEs), all of
which were assessed by the investigator as being unrelated
to the study treatment.
Fig. 2. Comparison of the response rates associated with NASHA
in three subgroups of the ITT population: patients with generalized
OA, bilateral OA of the knee, and unilateral OA of the knee.
647Osteoarthritis and Cartilage Vol. 12, No. 8The safety outcomes in the subgroup of patients with OA
conﬁned to the knee (216 patients) were similar to those for
the overall population. In the subgroup, a total of 290 AEs
were reported among 62.6% of the patients. Treatment-
related AEs were reported by 12 patients (11.2%) in the
NASHA group, compared with 6 (5.5%) in the saline group.
As in the overall population, arthralgia was the most
common AE.
Discussion
This trial is the ﬁrst placebo-controlled investigation of
a single injection of NASHA for OA of the knee. There was
a favorable reduction in pain with NASHA that began by
2 weeks and persisted throughout the 26-week protocol.
However, for the overall population there was no between-
group difference in the response rate at any time-point.
Despite the failure to achieve a between-group difference
in the primary efﬁcacy variable, there are important
messages within our data. In the subset analysis, it appears
that there is potential interference in the evaluation from
symptomatic OA at other sites. If one examines those with
OA conﬁned to one or both knees, there was a difference
between the NASHA and placebo study groups at 6 weeks
(42.1% vs 27.5%; P ¼ 0:025). In addition, a higher NASHA-
associated response rate was obtained in patients with OA
conﬁned to the knee compared with the overall ITT
population at all time-points (Fig. 2). The subgroup with
OA restricted to the signal knee differed in that there were
fewer NSAID/analgesic users at screeningdcorrespond-
ingly, the use of rescue medication was considerably lower
in this group than in patients with generalized OA. It is
possible that the ability to measure the efﬁcacy of a local
intra-articular agent was hindered by the lack of a general-
ized effect (e.g., as might be expected with an oral
medication).
Although the subgroup of patients with OA conﬁned to the
knee is likely to reﬂect more closely the true treatment effect
with NASHA, it must be borne in mind that within that group
there was a potential confounding factor. One hundred and
thirty-four patients (62%) presented with bilateral knee OA,
which, owing to the difﬁculty of identifying the exact source
of pain, could have masked the treatment effect of NASHA.
This notion is supported by the observation that the greatest
NASHA-associated response rate was observed in the
subgroup of 82 patients who presented with unilateral OA
(Fig. 2). In this comparatively homogeneous patient pop-
Table IV
Breakdown of AE occurrence and relationship to treatment over the
study period
Adverse events NASHA (N ¼ 173) Saline (N ¼ 174)
No. of patients
affected (%)
No. of patients
affected (%)
Non-serious 112 (64.7%) 114 (65.5%)
Treatment-related 22 (12.7%) 15 (8.0%)
Related to
device only
3 (1.7%) 2 (1.1%)
Related to
injection only
1 (0.6%) 2 (1.1%)
Treatment-unrelated 101 (58.3%) 109 (63.0%)
Serious 7 (4.0%) 3 (1.7%)
Treatment-related 0 (0.0%) 0 (0.0%)
Treatment-unrelated 7 (4.0%) 3 (1.7%)ulation, the difference in responder rate between NASHA
and saline was even more pronounced at 6 weeks,
although results for this group need to be interpreted with
caution owing to the small number of patients (less than
one-third of the sample size calculated for the original com-
parison). In addition, there was no adjustment for multiple
comparisons in this analysis.
Thepresent study tested a single injection. The logic for the
single injection was based on the proposed beneﬁt of a long
intra-articular half-life of NASHA (4 weeks) in knee joints of
healthy volunteers19. The long residence half-life is attribut-
able to the stabilized network of HA molecules within
NASHA16. HAmolecules within this network ( gel) are unable
to move freely and therefore not readily available to be
degraded by the synovial cells that degrade unmodiﬁed HA;
i.e., these cells are only able to engulf free HA molecules.
Several intra-articular HAs have been shown to be bene-
ﬁcial for OA of the knee14,20,21. However, unlike NASHA
these HAs have required 3e5 weekly injections, which may
be due to more rapid degradation following injection into the
joint12. Animal studies have demonstrated that unmodiﬁed
HAhas a half-life of 24 h or less22e26. OneHA (HylanG-F 20)
has two HA components, one with a half-life of 1.5 days and
the other is extensively cross-linkedwith a half-life of 8.8 days
(present in a 4:1 ratio). The half-life of HylanG-F 20 is shorter
and the total dose of HA is less than with NASHA27.
The next important ﬁnding is related to the timing of
clinical effect. The duration of response in the present study
is consistent with the half-life of NASHA. Peak efﬁcacy with
NASHA occurred at 6 weeks, by which time approximately
one-third of the injected material may be expected to remain
in the joint in accordance with its 4-week half-life19.
Assuming that NASHA is effective in the majority of patients
for between 6 and 13 weeks post-treatment, re-injection
around this time could and probably should be considered.
Such an injection schedule would be a signiﬁcant advance
compared with previously available hyaluronic acid prepa-
rations, which require weekly injections for a period of 3e5
weeks. It should also be borne in mind that in the present
study a prolonged response to 26 weeks was apparent in
the majority of patients who were responders at 6 weeks,
raising the possibility that re-injection could be delayed to
26 weeks in some patients. Although a prolonged response
was also evident in the placebo group, it is our opinion that
this ﬁnding is consistent with the notion that the study was
confounded, possibly by the inclusion of subjects with
generalized OA.
Blinding was carefully monitored. The results of examin-
ing the patient’s awareness of receiving the NASHA or the
placebo were consistent with effective blinding of evaluating
investigators and patients, as well as the broadly similar
efﬁcacy in the two groups.
Treatment-related AEs (mainly arthralgia) occurred with
similar frequency in the NASHA and saline groups. The
favorable AE proﬁle for NASHA demonstrated in this study
is consistent with previously reported safety and tolerability
for NASHA from its alternative applications (cosmetic
surgery as well as treatment of vesicoureteral reﬂux and
stress urinary incontinence)11,28. Presently available HA
preparations are derived from rooster combs. Although the
HA is highly puriﬁed, there remain some potential concerns
regarding allergy to chicken products and, possibly,
presence of viruses or other animal-derived infectious
agents. Since NASHA is produced entirely in a laboratory
environment using non-animal sources, the risk of contam-
ination with allergens or infectious agents of animal origin is
minimal (theoretically zero). No immune reactions have
648 R. D. Altman et al.: NASHA in OA of the kneebeen reported with the NASHA, whereas there have been
reported reactions to the animal derived HAs including local
inﬂammation at the injection site, anaphylactoid reactions,
pseudoseptic reactions and granuloma formation29e31.
In conclusion, although NASHA failed to demonstrate
statistical beneﬁt over placebo, NASHA was found to be
superior to placebo in the subset of patients with OA
isolated to the signal knee; this superiority was present at 6
weeks, consistent with the half-life of the agent. Thus,
treatment with NASHA may require injections at intervals of
6e13 weeks, compared with 1 week for previously available
HA preparations. Additional studies are needed to establish
whether a deﬁned population with OA of the knee will
demonstrate a beneﬁt in response to intra-articular NASHA
and to establish the optimal approach to re-injection of this
agent and other HA preparations.
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